Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 9/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 9/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902525 | 0.88 | BTK (0.52) | CSNK1DCSNK1ECSF1RBTK | |
| SCHEMBL21753546 | 0.82 | CSF1R (0.45) | CSNK1DCSNK1ECSF1RBTKMAPK14 | |
| SCHEMBL20028732 | 0.77 | BTK (0.56) | BTKKMT2A | |
| SCHEMBL21753543 | 0.76 | CSNK1D (0.44) | CSNK1DCSNK1EKMT2A | |
| SCHEMBL21753537 | 0.76 | CSF1R (0.44) | CSF1RMEN1KMT2AMAPK14 | |
| SCHEMBL20351779 | 0.73 | MET (0.45) | TOP2ATOP2BDPP4 | |
| SCHEMBL1555194 | 0.73 | CSNK1D (0.42) | CSNK1DCSNK1EBTKMAPK13MAPK12 | |
| SCHEMBL23152069 | 0.73 | RECQL (0.50) | MEN1KMT2A | |
| SCHEMBL28876388 | 0.72 | CSNK1D (0.43) | CSNK1DCSNK1EBTKMEN1KMT2A | |
| SCHEMBL18017550 | 0.72 | BTK (0.57) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842425-B1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-05-22 | — | — | EP | disclosed |
| CN-110857293-B | Novel quinoline derivative inhibitor | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-112625027-B | Heterocyclic derivatives and use thereof | 药捷安康(南京)科技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4036086-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2022-08-03 | — | — | EP | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-112625027-A | Heterocyclic derivatives and use thereof | 南京药捷安康生物科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2021057782-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057782-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-110857293-A | Novel quinoline derivative inhibitor | 南京药捷安康生物科技有限公司 | 2020-03-03 | — | — | CN | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | CSNK1D 462/4885CSNK1E 203/4885CSF1R 1/4885 |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | RET, MERTK, MIF | CSNK1D 676/4885CSNK1E 432/4885CSF1R 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.